PA-COHESIVE-COMP/OXPLUS
5.10.2021 22:03:10 CEST | Business Wire | Press release
The Cohesive Companies, a wholly-owned but independently operated digital integrator business unit of Bentley Systems, Incorporated (Nasdaq:BSY), the infrastructure engineering software company, today announced its acquisition of OXplus, the leading rail asset management specialist headquartered in Veghel, Netherlands. The acquisition coincides with the appointment of Dr. Mark Bew MBE as CEO of The Cohesive Companies, succeeding Noah Eckhouse, who has retired after 17 years of exemplary service within Bentley Systems capped by the successful convergence, from multiple predecessor organizations, of The Cohesive Companies in 2020. OXplus becomes the sixth brand to enter The Cohesive Companies fold in support of its mission to deliver the strongest social, economic, and environmental outcomes for infrastructure clients and their constituents.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005250/en/
OXplus supports rail owners, operators, and maintainers, and rolling stock manufacturers around the globe with digital tools and solutions that give them a deep insight into the performance of their assets. It builds smart systems, and delivers standout client experiences, that use IoT data to effectively predict when repair or intervention is needed, that prevent downtime, that reduce operational costs, and that enable efficient scheduling of assets. The acquisition of OXplus, founded in 2010, will accelerate The Cohesive Companies’ expansion of its Enterprise Asset Management presence within Europe and elsewhere. For instance, OXplus has recently supported the prestigious Riyadh Metro project, the largest single-phase metro project underway globally, and is also supporting Siemens Mobility to efficiently execute the maintenance of Riyadh Metro’s new train fleet.
Bew joined Bentley Systems and The Cohesive Companies with its 2020 acquisition of the UK-based built-environment consultancy PCSG, providing digital advisory services and solutions to world-leading owners and operators in the transportation sector. Representative clients and projects include HS2, Europe’s largest infrastructure project, in developing a digital twin of the entire rail system; Highways England (National Highways), operator of the UK strategic road network; and Heathrow Airport Ltd. Prior to his co-leadership of PCSG, Bew held information and business system leadership roles with Costain and URS-Scott Wilson. Based in London, Bew also chaired the UK government’s BIM Task Group, which led the work to embed digital techniques and processes within major UK public sector infrastructure programs.
In a further appointment, George Church has been named COO of The Cohesive Companies. Based in Boston, USA, Church brings a depth of knowledge and expertise gained through 27 years at Bentley Systems, including as senior vice president of its professional services business.
Mark Bew said, “We are delighted to welcome the OXplus team to enhance The Cohesive Companies’ balance across geographies and sectors. Our collective success and learning curves in delivering projects while working fully virtually throughout the pandemic has proven our growth strategy in globally bringing together and further attracting world-class talent resources. I take the helm from Noah Eckhouse enthusiastic about our unique strengths as a full lifecycle digital integrator, delivering transformational outcomes across the built and natural environment, independent of our clients’ investment choices among technology vendors. It is particularly meaningful to me that OXplus’ proficiencies in rail and transport operations and service optimization now helps us be able to fulfill the vision, expressed through the UK public sector’s digital twin aspirations, for improved social benefits from infrastructure.”
OXplus CEO Henri Snijders said, “We are excited that OXplus is joining The Cohesive Companies to strengthen our position as a leading digital consultancy in the railways and transportation sectors. I would like to thank all the team at OXplus for their work and dedication in making this milestone possible.”
Richard Van Dongen, OXplus CCO, added, “Advancements in going digital are driving improvements on major railways projects leading toward the breakthrough advantages of infrastructure and of rolling stock digital twins. We know that together, we can deliver even more operational value for the transportation sector.”
##
About The Cohesive Companies
The Cohesive Companies form a wholly owned but independently operated business unit of Bentley Systems (Nasdaq:BSY, the infrastructure engineering software company www.bentley.com ). The Cohesive Companies provide advisory, systems integration, and technology strategies and services to help owner-operators advance their BIM, enterprise asset management (EAM), asset lifecycle information (ALIM), and asset performance modeling environments. Our uniquely comprehensive expertise in infrastructure digital twins spans from development platforms to operational systems, from cloud to mobile, from asset delivery to customer service optimization, and beyond resourceful technology implementation to change management and business process redesign. The Cohesive Companies have coalesced and globally multiplied the reach and capabilities of Cohesive Solutions, Cohesive Asset Performance, SRO Solutions, PCSG, Ontracks Consulting, and OXplus. www.cohesivecompanies.com
© 2021 Bentley Systems, Incorporated. Bentley, Cohesive Solutions, Cohesive Asset Performance, Ontracks, OXplus, PCSG, SRO Solutions, and The Cohesive Companies are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005250/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
